Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).

Chen R. W. , Ansell S. M. , Gallamini A., Connors J. M. , Savage K. J. , Collins G. P. , ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI İndekslerine Giren Dergi) identifier